Obesity - Pipeline Review, H2 2016

Date: November 9, 2016
Pages: 537
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O5F2BC0D9C1EN
Leaflet:

Download PDF Leaflet

Obesity - Pipeline Review, H2 2016
Obesity - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity – Pipeline Review, H2 2016, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.

Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obesity – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 15, 16, 128, 33 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 46 and 14 molecules, respectively.Obesity.

Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Obesity Overview
Therapeutics Development
Obesity - Therapeutics under Development by Companies
Obesity - Therapeutics under Investigation by Universities/Institutes
Obesity - Pipeline Products Glance
Obesity - Products under Development by Companies
Obesity - Products under Investigation by Universities/Institutes
Obesity - Companies Involved in Therapeutics Development
Obesity - Therapeutics Assessment
Drug Profiles
Obesity - Dormant Projects
Obesity - Discontinued Products
Obesity - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Obesity, H2 2016
Number of Products under Development for Obesity - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Obesity - Pipeline by Abeome Corporation, H2 2016
Obesity - Pipeline by Acylin Therapeutics Inc, H2 2016
Obesity - Pipeline by Advinus Therapeutics Ltd, H2 2016
Obesity - Pipeline by Aegis Therapeutics, LLC, H2 2016
Obesity - Pipeline by Akron Molecules AG, H2 2016
Obesity - Pipeline by Alize Pharma SAS, H2 2016
Obesity - Pipeline by Amabiotics SAS, H2 2016
Obesity - Pipeline by Amgen Inc., H2 2016
Obesity - Pipeline by Aoxing Pharmaceutical Company, Inc, H2 2016
Obesity - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
Obesity - Pipeline by AstraZeneca Plc, H2 2016
Obesity - Pipeline by Asubio Pharma Co., Ltd., H2 2016
Obesity - Pipeline by Athersys, Inc., H2 2016
Obesity - Pipeline by Biophytis SAS, H2 2016
Obesity - Pipeline by BioRestorative Therapies, Inc., H2 2016
Obesity - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Obesity - Pipeline by Braasch Biotech LLC, H2 2016
Obesity - Pipeline by C3 Jian, Inc, H2 2016
Obesity - Pipeline by Carmot Therapeutics Inc, H2 2016
Obesity - Pipeline by Chronos Therapeutics Limited, H2 2016
Obesity - Pipeline by CohBar, Inc., H2 2016
Obesity - Pipeline by CoMentis, Inc., H2 2016
Obesity - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016
Obesity - Pipeline by Corium International, Inc., H2 2016
Obesity - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Obesity - Pipeline by Diabetica Limited, H2 2016
Obesity - Pipeline by DiscoveryBiomed, Inc., H2 2016
Obesity - Pipeline by Eli Lilly and Company, H2 2016
Obesity - Pipeline by Esperion Therapeutics, Inc., H2 2016
Obesity - Pipeline by Eternygen GmbH, H2 2016
Obesity - Pipeline by Evotec AG, H2 2016
Obesity - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Obesity - Pipeline by FibroGen Inc, H2 2016
Obesity - Pipeline by Galenea Corp., H2 2016
Obesity - Pipeline by Gila Therapeutics Inc, H2 2016
Obesity - Pipeline by Gilead Sciences, Inc., H2 2016
Obesity - Pipeline by GlaxoSmithKline Plc, H2 2016
Obesity - Pipeline by GTx, Inc., H2 2016
Obesity - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
Obesity - Pipeline by Handok Inc., H2 2016
Obesity - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
Obesity - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
Obesity - Pipeline by Immungenetics AG, H2 2016
Obesity - Pipeline by Intarcia Therapeutics, Inc., H2 2016
Obesity - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
Obesity - Pipeline by Ixchel Pharma, LLC, H2 2016
Obesity - Pipeline by Jenrin Discovery, Inc., H2 2016
ity - Pipeline by Johnson & Johnson, H2 2016
Obesity - Pipeline by Lead Discovery Center GmbH, H2 2016
Obesity - Pipeline by Leading BioSciences, Inc., H2 2016
Obesity - Pipeline by LEO Pharma A/S, H2 2016
Obesity - Pipeline by LG Life Science LTD., H2 2016
Obesity - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016
Obesity - Pipeline by M Pharmaceutical Inc., H2 2016
Obesity - Pipeline by Magnus Life Ltd, H2 2016
Obesity - Pipeline by MAKScientific, LLC, H2 2016
Obesity - Pipeline by MedImmune LLC, H2 2016
Obesity - Pipeline by Merck & Co., Inc., H2 2016
Obesity - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016
Obesity - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Obesity - Pipeline by NeuroNano Pharma Inc, H2 2016
Obesity - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016
Obesity - Pipeline by NIBEC, H2 2016
Obesity - Pipeline by Nordic Bioscience A/S, H2 2016
Obesity - Pipeline by Novo Nordisk A/S, H2 2016
Obesity - Pipeline by ObeTherapy Biotechnology, H2 2016
Obesity - Pipeline by Ogeda SA, H2 2016
Obesity - Pipeline by Omeros Corporation, H2 2016
Obesity - Pipeline by OPKO Biologics Ltd, H2 2016
Obesity - Pipeline by OPKO Health, Inc., H2 2016
Obesity - Pipeline by Orbis Biosciences Inc, H2 2016
Obesity - Pipeline by Orexigen Therapeutics, Inc., H2 2016
Obesity - Pipeline by Pfizer Inc., H2 2016
Obesity - Pipeline by PharmaIN Corporation, H2 2016
Obesity - Pipeline by Poxel SA, H2 2016
Obesity - Pipeline by Progenra, Inc., H2 2016
Obesity - Pipeline by Prometheon Pharma, LLC, H2 2016
Obesity - Pipeline by ReCyte Therapeutics, Inc., H2 2016
Obesity - Pipeline by Renova Therapeutics Inc, H2 2016
Obesity - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
Obesity - Pipeline by Saniona AB, H2 2016
Obesity - Pipeline by Sanofi, H2 2016
Obesity - Pipeline by Selvita S.A., H2 2016
Obesity - Pipeline by Seoul Pharma Co., Ltd., H2 2016
Obesity - Pipeline by Shionogi & Co., Ltd., H2 2016
- Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2016
Obesity - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
Obesity - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Obesity - Pipeline by Toray Industries, Inc., H2 2016
Obesity - Pipeline by Umecrine AB, H2 2016
Obesity - Pipeline by Vicore Pharma AB, H2 2016
Obesity - Pipeline by Viking Therapeutics, Inc., H2 2016
Obesity - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2016
Obesity - Pipeline by Xenetic Biosciences (UK) Limited, H2 2016
Obesity - Pipeline by XL-protein GmbH, H2 2016
Obesity - Pipeline by Yuyu Pharma, Inc., H2 2016
1`OBESITY - PIPELINE BY ZAFGEN INC., H2 2016
Obesity - Pipeline by Zealand Pharma A/S, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Obesity - Dormant Projects, H2 2016
Obesity - Dormant Projects (Contd..1), H2 2016
Obesity - Dormant Projects (Contd..2), H2 2016
Obesity - Dormant Projects (Contd..3), H2 2016
Obesity - Dormant Projects (Contd..4), H2 2016
Obesity - Dormant Projects (Contd..5), H2 2016
Obesity - Dormant Projects (Contd..6), H2 2016
Obesity - Dormant Projects (Contd..7), H2 2016
Obesity - Dormant Projects (Contd..8), H2 2016
Obesity - Dormant Projects (Contd..9), H2 2016
Obesity - Dormant Projects (Contd..10), H2 2016
Obesity - Dormant Projects (Contd..11), H2 2016
Obesity - Dormant Projects (Contd..12), H2 2016
Obesity - Dormant Projects (Contd..13), H2 2016
Obesity - Dormant Projects (Contd..14), H2 2016
Obesity - Dormant Projects (Contd..15), H2 2016
Obesity - Dormant Projects (Contd..16), H2 2016
Obesity - Dormant Projects (Contd..17), H2 2016
Obesity - Dormant Projects (Contd..18), H2 2016
Obesity - Dormant Projects (Contd..19), H2 2016
Obesity - Dormant Projects (Contd..20), H2 2016
Obesity - Dormant Projects (Contd..21), H2 2016
Obesity - Dormant Projects (Contd..22), H2 2016
Obesity - Dormant Projects (Contd..23), H2 2016
Obesity - Dormant Projects (Contd..24), H2 2016
Obesity - Discontinued Products, H2 2016
Obesity - Discontinued Products (Contd..1), H2 2016
Obesity - Discontinued Products (Contd..2), H2 2016
Obesity - Discontinued Products (Contd..3), H2 2016
Obesity - Discontinued Products (Contd..4), H2 2016
Obesity - Discontinued Products (Contd..5), H2 2016
Obesity - Discontinued Products (Contd..6), H2 2016

LIST OF FIGURES

Number of Products under Development for Obesity, H2 2016
Number of Products under Development for Obesity - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Abdominal Obesity - Pipeline Review, H1 2015 US$ 1,600.00 Jun, 2015 · 55 pages
Seek - Product Pipeline Review - 2014 US$ 1,125.00 Oct, 2014 · 42 pages
Galenea Corp. - Product Pipeline Review - 2015 US$ 1,200.00 May, 2015 · 21 pages

Ask Your Question

Obesity - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: